INNO Share Price | InnoCan Pharma Corp. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare InnoCan Pharma Corp. with Similar Stocks

BioSyent, Inc.Defence Therapeutics Inc NervGen Pharma Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

The company has declared Negative results for the last 4 consecutive quarters

NET PROFIT(9M) At CAD -2.5 MM has Grown at -121.78%
INTEREST(HY) At CAD 0.03 MM has Grown at 222.57%
DEBTORS TURNOVER RATIO(HY) Lowest at 23.76 times

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 11 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-52.20%

Price to Book

1.46

Revenue and Profits:

Net Sales:

7 Million

(Quarterly Results - Jun 2026)

Net Profit:

0 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

1090.0%

6 Months

981.82%

1 Year

750.0%

2 Years

1006.98%

3 Years

349.06%

4 Years

376.0%

5 Years

1342.42%

InnoCan Pharma Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

104.61%

EBIT Growth (5y)

9.58%

EBIT to Interest (avg)

-3.86

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

4.72

Tax Ratio

30.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.80

EV to EBIT

-1.64

EV to EBITDA

-1.66

EV to Capital Employed

-5.71

EV to Sales

0.16

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-52.20%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -17.98% vs 27.14% in Mar 2026",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 83.33% vs -146.15% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7.30",
          "val2": "8.90",
          "chgp": "-17.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-1.10",
          "chgp": "36.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.40",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.20",
          "val2": "-1.20",
          "chgp": "83.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-96.80%",
          "val2": "-121.60%",
          "chgp": "2.48%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -7.69% vs 119.02% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -25.00% vs 92.98% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "37.20",
          "val2": "40.30",
          "chgp": "-7.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-1.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.80",
          "val2": "3.00",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.50",
          "val2": "-0.40",
          "chgp": "-25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-47.20%",
          "val2": "-42.40%",
          "chgp": "-0.48%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

7.30

8.90

-17.98%

Operating Profit (PBDIT) excl Other Income

-0.70

-1.10

36.36%

Interest

0.00

Exceptional Items

0.40

-0.00

Consolidate Net Profit

-0.20

-1.20

83.33%

Operating Profit Margin (Excl OI)

-96.80%

-121.60%

2.48%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is -17.98% vs 27.14% in Mar 2026

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 83.33% vs -146.15% in Mar 2026

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

37.20

40.30

-7.69%

Operating Profit (PBDIT) excl Other Income

-1.70

Interest

0.00

Exceptional Items

1.80

3.00

-40.00%

Consolidate Net Profit

-0.50

-0.40

-25.00%

Operating Profit Margin (Excl OI)

-47.20%

-42.40%

-0.48%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -7.69% vs 119.02% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -25.00% vs 92.98% in Dec 2024

All Annual Results

Company CV

About InnoCan Pharma Corp.

InnoCan Pharma Corp.

Pharmaceuticals & Biotechnology

Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.

Company Coordinates

Company Details

10 Hamenofim Street , HERZLIYA None : 4672561

Tel:

https://innocanpharma.com/

Registrar Details

Footer loading